QIAGEN Clinical Insight (QCI) Interpret One

Deliver oncologist-ready variant interpretation reports

Features

  • Access to over 300,000 variant-specific molecular impact summaries
  • Weekly updated therapeutic, prognostic, diagnositc evidence, including drug labels, recruiting clinical trials, practice guidelines, and clinical/functional studies
  • Access to over 300,000 variant-specific articles
  • Access to >25 databases, including COSMIC, ClinVar, gnomAD, AFC
  • Access to AMP- and ACMG-based variant classifications for every variant in over 31,000 cancer types
S_9986_QCI_InterpretOne_iS474202902

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

QCII One PreCur 301-600 Genes 24 pck

Cat. No. / ID: 830809

24 QCI Interpret One (Pre-curated) Test Analysis of up to 600 genes. To be used within 365 days.
The QIAGEN Clinical Insight (QCI) Interpret One is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

✓ 24/7 automatic processing of online orders

✓ Knowledgeable and professional Product & Technical Support

✓ Fast and reliable (re)-ordering

Product Details

With QCI Interpret One, variant scientists and lab directors can prepare, prioritize and report on clinically relevant variants associated with solid tumors and hematological malignancies without the time-consuming step of researching and writing variant- and disease-specific evidence summaries. QCI Interpret One instantly delivers concise, oncologist-reviewed evidence for each biomarker in the context of the cancer sub-type, listing information on the mutation’s molecular characteristics, roles in disease, and therapeutic, prognostic, and diagnostic implications. Users get access to an “expert second opinion” for variant classification and can deliver professional reports directly to physicians and oncologists to better inform clinical decision-making.

Performance

QCI Interpret One is a clinical decision support tool that combines flexible and automatable software, powered by superior structured content in the QIAGEN Clinical Knowledge Base, with the trusted interpretation services of N-of-One, a QIAGEN Company.
With over a decade of experience in clinical genomics interpretation for oncology, QIAGEN's variant scientist team interprets over 10,000 oncology cases monthly and has interpreted more than 350,000 tumor samples for pathologists and lab directors.
With QCI Interpret One, you can reduce hands-on time with configurable and automatable NGS interpretation workflows. Plus, you can access preconfigured, ready-to-use workflows for QIAGEN and commercial panels. The software also lets you customize your lab’s specific reporting policies to automate variant reporting and drug and trial selection, and you can leverage a feature-rich API to integrate with your LIMS to scale-up your case processing.

Applications

QCI Interpret One is designed to augment in-house expertise. By providing you with all of the content necessary to generate a comprehensive, patient-specific report, yet giving you full control over final classifications, comments, and recommendations, the software and service enhance decision-making in the clinical workflow.

Publications

Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer.
Winn JS; Hasse Z; Slifker M; Pei J; Arisi-Fernandez SM; Talarchek JN; Obeid E; Baldwin DA; Gong Y; Ross E; Cristofanilli M; Alpaugh RK; Fernandez SV;
Int J Mol Sci; 2020; 21 (4) 2020 Feb 14 PMID:32075053
The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B;
BMC Cancer; 2021; 21 (1):234 2021 Mar 6 PMID:33676450
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.
Rothwell DG; Ayub M; Cook N; Thistlethwaite F; Carter L; Dean E; Smith N; Villa S; Dransfield J; Clipson A; White D; Nessa K; Ferdous S; Howell M; Gupta A; Kilerci B; Mohan S; Frese K; Gulati S; Miller C; Jordan A; Eaton H; Hickson N; O'Brien C; Graham D; Kelly C; Aruketty S; Metcalf R; Chiramel J; Tinsley N; Vickers AJ; Kurup R; Frost H; Stevenson J; Southam S; Landers D; Wallace A; Marais R; Hughes AM; Brady G; Dive C; Krebs MG;
Nat Med; 2019; 25 (5):738-743 2019 Apr 22 PMID:31011204